MedPlus Health Services Limited has informed stock exchanges about a regulatory action affecting its subsidiary operations. The company disclosed that Optival Health Solutions Private Limited, a subsidiary of MedPlus Health Services, has received a suspension order for a drug license of a store located in Maharashtra.

Regulatory Action Details

The suspension order was issued by the Assistant Commissioner Licensing Authority, Food Drug Administrations, Ahmednagar, Maharashtra. The order affects a store situated at Bhandari Colony, Ahmednagar, Maharashtra, and imposes a ten-day suspension of the drug license.

Financial Impact

The company has quantified the potential financial impact of this regulatory action. MedPlus Health Services estimates a potential revenue loss of ₹2.00 lakhs due to the ten-day suspension of the drug license for the affected store.

Compliance Disclosure

This disclosure was made pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, read with SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024. The company has informed both BSE Limited and National Stock Exchange of India Limited about this regulatory development as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Detailed information regarding this matter will be available on the company's website at www.medplusindia.com and also on the websites of BSE Limited and National Stock Exchange of India Limited.

Medplus Health Services Limited has informed stock exchanges about regulatory action taken against its subsidiary, involving the suspension of drug licenses for multiple store locations in Maharashtra.

Subsidiary Faces License Suspension Orders

Optival Health Solutions Private Limited, a subsidiary of Medplus Health Services, has received three suspension orders for drug licenses affecting stores in Maharashtra. The orders were received on December 13, 2025, from the Assistant Commissioner Licensing Authority, Food Drug Administration, Maharashtra.

The suspensions target stores located in Amravati and Nagpur districts, with each suspension lasting five days. The regulatory action has been taken under Rule 65 of the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945.

Financial Impact Assessment

The company has quantified the potential revenue impact from these license suspensions across the affected locations:

The total potential revenue loss across the affected locations is estimated at ₹10.17 lakhs.

Regulatory Compliance and Disclosure

The disclosure has been made pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, read with SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024. These regulations require listed entities to disclose material events affecting their operations or subsidiaries.

The company has stated that detailed information regarding this matter will be available on its official website at www.medplusindia.com , as well as on the websites of BSE Limited and National Stock Exchange of India Limited. This ensures transparency and accessibility of information for all stakeholders and regulatory compliance requirements.